Mannkind CorpMNKD

MannKind Corporation lost $16.6 million in the quarter to 31 March 2026 while booking $90.2 million in product revenue, according to the latest 10-Q. The company’s operating income was a modest deficit of $1.7 million, and its quarterly cash burn from operations hit $5.4 million. Liabilities exceed assets by $59.2 million, leaving shareholders’ equity at a negative $59.2 million. Cash and short-term investments totalled $133.8 million at quarter-end, but the company is still running an accounting overdraft on its balance sheet.

MannKind describes itself as a company dedicated to helping more people live life more humanly, and its pipeline page promises new products and collaborations aimed at helping people take control of their health and even thrive. The platform story is uplifting; the numbers are not. The company’s latest 10-Q shows inventory rising $14.9 million to $49.2 million over the quarter, a build that can either signal healthy channel fill or a commercial slowdown depending on what actually ships and what gets written down. The company’s short-term investments are up $81 million, but its operating cash flow is down $5.4 million, which means the cash pile is being preserved rather than generated.

Revenue for the quarter came in at $90.2 million, which is the headline figure, but the net loss of $16.6 million tells the real story. MannKind’s operating loss was $1.7 million and its diluted EPS was minus 5 cents. The weighted average diluted share count stood at 308.3 million shares. The company’s assets totalled $744.4 million while liabilities reached $803.6 million, leaving a shareholders’ equity deficit of $59.2 million. The company spent $1.9 million on property, plant, and equipment during the quarter, a small but necessary line item for a company that still needs to manufacture and distribute its inhaled insulin technology. (source: Revenue from Contract with Customer, Excluding Assessed Tax: $90.2M; Net Income (Loss) Attributable to Parent: $-16.6M; Operating Income (Loss): $-1.7M; Assets: $744.4M; Liabilities: $803.6M; Stockholders' Equity Attributable to Parent: $-59.2M; Cash and Cash Equivalents, at Carrying Value: $52.8M; Short-term Investments: $81.0M; Net Cash Provided by (Used in) Operating Activities: $-5.4M; Payments to Acquire Property, Plant, and Equipment: $1.9M; Inventory, Net: $49.2M; Increase (Decrease) in Inventories: $14.9M; Earnings Per Share, Diluted: $-0.05; Weighted Average Number of Shares Outstanding, Diluted: 308.3M shares; 10-Q period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/899460/000119312526163221/0001193125-26-000106-index.htm)

The company’s Form 4 disclosures show that several restricted stock units granted on 25 May 2023 vested on 15 July 2026 after the compensation committee certified that performance objectives had been met. The awards were disclosed in multiple Form 4 filings filed on 17 July 2026, each noting the same vesting date and performance criteria. MannKind’s pipeline and collaborations page promises new products and applications of its inhaled insulin platform, but the 10-Q does not yet show revenue from these programmes. The company’s diluted share count is 308.3 million and its diluted EPS is minus 5 cents, so dilution remains a live topic. (source: MNKD 4 (2026-07-17), https://www.sec.gov/Archives/edgar/data/899460/000119312526308134/xslF345X06/ownership.xml; MNKD 4 (2026-07-17), https://www.sec.gov/Archives/edgar/data/899460/000119312526308133/xslF345X06/ownership.xml; MNKD 4 (2026-07-17), https://www.sec.gov/Archives/edgar/data/899460/000119312526308132/xslF345X06/ownership.xml; MNKD 4 (2026-07-17), https://www.sec.gov/Archives/edgar/data/899460/000119312526308137/xslF345X06/ownership.xml; MNKD 4 (2026-07-17), https://www.sec.gov/Archives/edgar/data/899460/000119312526308139/xslF345X06/ownership.xml; Pipeline - MannKind Corporation, https://mannkindcorp.com/pipeline/)

The company’s 8-K filed on 24 July 2026 is light on detail but confirms an update to a prior disclosure. The filing index on the SEC’s EDGAR portal lists the company’s recent submissions, including the 8-K and multiple Form 4s, but does not add new financial data. MannKind’s site continues to host mission statements and pipeline descriptions rather than hard numbers on product launches or regulatory approvals. Until the next 10-Q or a surprise update, the headline remains revenue of $90.2 million, a net loss of $16.6 million, and an equity deficit of $59.2 million. (source: MNKD 8-K (2026-07-24), https://www.sec.gov/Archives/edgar/data/899460/000119312526316041/d63182d8k.htm; MannKind SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=899460; MannKind SEC submissions JSON, https://data.sec.gov/submissions/CIK0000899460.json)

The company’s latest SEC companyfacts JSON feed contains XBRL tagged data, but the JSON itself does not add new narrative information beyond what is in the 10-Q. MannKind’s website hosts high-level mission statements and product pipeline pages, but the site does not provide granular revenue or cashflow breakdowns beyond the quarterly filings. The absence of detailed segment data or product-level revenue in the public domain limits the granularity of external analysis. (source: MannKind SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0000899460.json; About MannKind's Mission - Our Corporation's Legacy & Values, https://www.mannkindcorp.com/about)